Aishwarya Shaji
Akanksha Verma
Ashima Bhaskar
Ved Prakash Dwivedi- Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
A Correction on
BCG and beyond: unlocking new frontiers in TB vaccine development
By Shaji A, Verma A, Bhaskar A and Dwivedi VP (2025) Front. Immunol. 16:1608104. doi: 10.3389/fimmu.2025.1608104
In the Abstract irrelevant text was inserted erroneously during production.
The Abstract has been corrected to read:
“With over 10 million new cases and 1.6 million deaths annually, tuberculosis (TB) continues to be a significant worldwide health-burden. To assist in curbing the spread of TB, the century-old BCG, which is a live-attenuated vaccine, is now the only licensed TB vaccine used in humans. However, BCG’s limited efficacy and poor antigenicity in adults have evoked the need to design new vaccines against TB. The limited parameter is the availability of potent antigens; as a consequence, it is imperative to study the Mycobacterium tuberculosis (Mtb)-specific antigens that can provide a stronger immune response if included in vaccine candidates. Through this review, we aim to concentrate on the progress of current vaccine-candidates undergoing preclinical and clinical-studies. Moreover, it is not the pathogen but the genetics of the host that plays an essential role in fine tuning the immune-response and susceptibility to TB. Over the past 50 years, a systematic approach to treating TB patients has overlooked factors like pharmacokinetics, immune-response, and treatment duration. Henceforth, this review highlights the precision medicine-guided approach considering genetic makeup and host immunity that could influence clinical management choices. The consolidated review will shed light on advancements in vaccine-candidates, which can be harnessed in prophylactic development against TB.’’
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: tuberculosis, BCG, trained immunity, vaccine, host genetics
Citation: Shaji A, Verma A, Bhaskar A and Dwivedi VP (2025) Correction: BCG and beyond: unlocking new frontiers in TB vaccine development. Front. Immunol. 16:1677868. doi: 10.3389/fimmu.2025.1677868
Received: 01 August 2025; Accepted: 14 August 2025;
Published: 25 August 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Shaji, Verma, Bhaskar and Dwivedi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ved Prakash Dwivedi, dmVkcHJha2FzaGJ0QGdtYWlsLmNvbQ==